Skip to main content
Top
Published in: Journal of Neuroinflammation 1/2017

Open Access 01-12-2017 | Research

Adaptive lymphocyte profiles correlate to brain Aβ burden in patients with mild cognitive impairment

Authors: Ann M. Stowe, Sara J. Ireland, Sterling B. Ortega, Ding Chen, Ryan M. Huebinger, Takashi Tarumi, Thomas S. Harris, C. Munro Cullum, Roger Rosenberg, Nancy L. Monson, Rong Zhang

Published in: Journal of Neuroinflammation | Issue 1/2017

Login to get access

Abstract

Background

We previously found that subjects with amnestic mild cognitive impairment exhibit a pro-inflammatory immune profile in the cerebrospinal fluid similar to multiple sclerosis, a central nervous system autoimmune disease. We therefore hypothesized that early neuroinflammation would reflect increases in brain amyloid burden during amnestic mild cognitive impairment.

Methods

Cerebrospinal fluid and blood samples were collected from 24 participants with amnestic mild cognitive impairment (12 men, 12 women; 66 ± 6 years; 0.5 Clinical Dementia Rating) enrolled in the AETMCI study. Analyses of cerebrospinal fluid and blood included immune profiling by multi-parameter flow cytometry, genotyping for apolipoprotein (APO)ε, and quantification of cytokine and immunoglobin levels. Amyloid (A)β deposition was determined by 18F-florbetapir positron emission tomography. Spearman rank order correlations were performed to assess simple linear correlation for parameters including amyloid imaging, central and peripheral immune cell populations, and protein cytokine levels.

Results

Soluble Aβ42 in the cerebrospinal fluid declined as Aβ deposition increased overall and in the precuneous and posterior cingulate cortices. Lymphocyte profiling revealed a significant decline in T cell populations in the cerebrospinal fluid, specifically CD4+ T cells, as Aβ deposition in the posterior cingulate cortex increased. In contrast, increased Aβ burden correlated positively with increased memory B cells in the cerebrospinal fluid, which was exacerbated in APOε4 carriers. For peripheral circulating lymphocytes, only B cell populations decreased with Aβ deposition in the precuneous cortex, as peripheral T cell populations did not correlate with changes in brain amyloid burden.

Conclusions

Elevations in brain Aβ burden associate with a shift from T cells to memory B cells in the cerebrospinal fluid of subjects with amnestic mild cognitive impairment in this exploratory cohort. These data suggest the presence of cellular adaptive immune responses during Aβ accumulation, but further study needs to determine whether lymphocyte populations contribute to, or result from, Aβ dysregulation during memory decline on a larger cohort collected at multiple centers.

Trial registration

AETMCI NCT01146717
Appendix
Available only for authorised users
Literature
2.
go back to reference Richard E, et al. Methodological challenges in designing dementia prevention trials—the European Dementia Prevention Initiative (EDPI). J Neurol Sci. 2012;322(1-2):64–70.CrossRefPubMed Richard E, et al. Methodological challenges in designing dementia prevention trials—the European Dementia Prevention Initiative (EDPI). J Neurol Sci. 2012;322(1-2):64–70.CrossRefPubMed
3.
go back to reference Kling MA, et al. Vascular disease and dementias: paradigm shifts to drive research in new directions. Alzheimers Dement. 2013;9(1):76–92.CrossRefPubMed Kling MA, et al. Vascular disease and dementias: paradigm shifts to drive research in new directions. Alzheimers Dement. 2013;9(1):76–92.CrossRefPubMed
4.
go back to reference Morris JK, et al. Is Alzheimer’s disease a systemic disease?, in Biochim Biophys Acta. 2014;1842(9):1340–1349. Morris JK, et al. Is Alzheimer’s disease a systemic disease?, in Biochim Biophys Acta. 2014;1842(9):1340–1349.
6.
go back to reference Villemagne VL, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–67.CrossRefPubMed Villemagne VL, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–67.CrossRefPubMed
7.
go back to reference Storandt M, et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009;66(12):1476–81.CrossRefPubMedPubMedCentral Storandt M, et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009;66(12):1476–81.CrossRefPubMedPubMedCentral
9.
go back to reference Iwata N, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6(2):143–50.CrossRefPubMed Iwata N, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6(2):143–50.CrossRefPubMed
10.
go back to reference Shibata M, et al. Clearance of Alzheimer’s amyloid-ss (1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106(12):1489–99.CrossRefPubMedPubMedCentral Shibata M, et al. Clearance of Alzheimer’s amyloid-ss (1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106(12):1489–99.CrossRefPubMedPubMedCentral
11.
go back to reference Iliff JJ, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012;4(147):147ra111. Iliff JJ, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012;4(147):147ra111.
13.
go back to reference Wyss-Coray T, et al. Inflammation in neurodegenerative disease—a double-edged sword. Neuron. 2002;35(3):419–32.CrossRefPubMed Wyss-Coray T, et al. Inflammation in neurodegenerative disease—a double-edged sword. Neuron. 2002;35(3):419–32.CrossRefPubMed
15.
go back to reference Tierney MC, et al. Prediction of probable Alzheimer’s disease in memory-impaired patients: a prospective longitudinal study. Neurology. 1996;46(3):661–5.CrossRefPubMed Tierney MC, et al. Prediction of probable Alzheimer’s disease in memory-impaired patients: a prospective longitudinal study. Neurology. 1996;46(3):661–5.CrossRefPubMed
16.
go back to reference Bowen J, et al. Progression to dementia in patients with isolated memory loss. Lancet. 1997;349(9054):763–5.CrossRefPubMed Bowen J, et al. Progression to dementia in patients with isolated memory loss. Lancet. 1997;349(9054):763–5.CrossRefPubMed
17.
go back to reference Monson NL, et al. Elevated CNS inflammation in patients with preclinical Alzheimer’s disease. J Cereb Blood Flow Metab. 2014;34(1):30–3.CrossRefPubMed Monson NL, et al. Elevated CNS inflammation in patients with preclinical Alzheimer’s disease. J Cereb Blood Flow Metab. 2014;34(1):30–3.CrossRefPubMed
18.
go back to reference Larbi A, et al. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer’s disease. J Alzheimers Dis. 2009;17(1):91–103.CrossRefPubMed Larbi A, et al. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer’s disease. J Alzheimers Dis. 2009;17(1):91–103.CrossRefPubMed
19.
go back to reference Pellicano M, et al. Immune profiling of Alzheimer patients. J Neuroimmunol. 2012;242(1–2):52–9.CrossRefPubMed Pellicano M, et al. Immune profiling of Alzheimer patients. J Neuroimmunol. 2012;242(1–2):52–9.CrossRefPubMed
20.
go back to reference Speciale L, et al. Lymphocyte subset patterns and cytokine production in Alzheimer’s disease patients. Neurobiol Aging. 2007;28(8):1163–9.CrossRefPubMed Speciale L, et al. Lymphocyte subset patterns and cytokine production in Alzheimer’s disease patients. Neurobiol Aging. 2007;28(8):1163–9.CrossRefPubMed
21.
go back to reference Lombardi VR, et al. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer’s disease (AD) individuals. J Neuroimmunol. 1999;97(1–2):163–71.CrossRefPubMed Lombardi VR, et al. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer’s disease (AD) individuals. J Neuroimmunol. 1999;97(1–2):163–71.CrossRefPubMed
22.
go back to reference Richartz-Salzburger E, et al. Altered lymphocyte distribution in Alzheimer’s disease. J Psychiatr Res. 2007;41(1–2):174–8.CrossRefPubMed Richartz-Salzburger E, et al. Altered lymphocyte distribution in Alzheimer’s disease. J Psychiatr Res. 2007;41(1–2):174–8.CrossRefPubMed
23.
go back to reference Clark CM, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275–83.CrossRefPubMed Clark CM, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275–83.CrossRefPubMed
27.
go back to reference Buckner RL, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709–17.CrossRefPubMed Buckner RL, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709–17.CrossRefPubMed
28.
go back to reference Hatashita S, et al. Diagnosed mild cognitive impairment due to Alzheimer’s disease with PET biomarkers of beta amyloid and neuronal dysfunction. Plos One. 2013;8(6):e66877.CrossRefPubMedPubMedCentral Hatashita S, et al. Diagnosed mild cognitive impairment due to Alzheimer’s disease with PET biomarkers of beta amyloid and neuronal dysfunction. Plos One. 2013;8(6):e66877.CrossRefPubMedPubMedCentral
29.
go back to reference Lueg G, et al. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer’s disease. Neurobiol Aging. 2015;36(1):81–9.CrossRefPubMed Lueg G, et al. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer’s disease. Neurobiol Aging. 2015;36(1):81–9.CrossRefPubMed
30.
go back to reference Adluru N, et al. White matter microstructure in late middle-age: effects of apolipoprotein E4 and parental family history of Alzheimer’s disease. Neuroimage Clin. 2014;4:730–42.CrossRefPubMedPubMedCentral Adluru N, et al. White matter microstructure in late middle-age: effects of apolipoprotein E4 and parental family history of Alzheimer’s disease. Neuroimage Clin. 2014;4:730–42.CrossRefPubMedPubMedCentral
31.
go back to reference Holtzman DM, et al. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(3):a006312.CrossRefPubMedPubMedCentral Holtzman DM, et al. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(3):a006312.CrossRefPubMedPubMedCentral
32.
go back to reference Taylor JL, et al. APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years. Neurobiol Aging. 2014;35(11):2479–85.CrossRefPubMedPubMedCentral Taylor JL, et al. APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years. Neurobiol Aging. 2014;35(11):2479–85.CrossRefPubMedPubMedCentral
33.
go back to reference Fryer JD, et al. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem. 2005;280(27):25754–9.CrossRefPubMed Fryer JD, et al. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem. 2005;280(27):25754–9.CrossRefPubMed
34.
go back to reference De Sanctis JB, et al. Expression of low-density lipoprotein receptors in peripheral blood and tonsil B lymphocytes. Clin Exp Immunol. 1998;113(2):206–12.CrossRefPubMedPubMedCentral De Sanctis JB, et al. Expression of low-density lipoprotein receptors in peripheral blood and tonsil B lymphocytes. Clin Exp Immunol. 1998;113(2):206–12.CrossRefPubMedPubMedCentral
35.
go back to reference Cirrito JR, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48(6):913–22.CrossRefPubMed Cirrito JR, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48(6):913–22.CrossRefPubMed
36.
go back to reference Pfefferbaum A, et al. Cerebral blood flow in posterior cortical nodes of the default mode network decreases with task engagement but remains higher than in most brain regions. Cereb Cortex. 2011;21(1):233–44.CrossRefPubMed Pfefferbaum A, et al. Cerebral blood flow in posterior cortical nodes of the default mode network decreases with task engagement but remains higher than in most brain regions. Cereb Cortex. 2011;21(1):233–44.CrossRefPubMed
37.
go back to reference Jozwik A, et al. Beta-amyloid peptides enhance the proliferative response of activated CD4CD28 lymphocytes from Alzheimer disease patients and from healthy elderly. Plos One. 2012;7(3):e33276.CrossRefPubMedPubMedCentral Jozwik A, et al. Beta-amyloid peptides enhance the proliferative response of activated CD4CD28 lymphocytes from Alzheimer disease patients and from healthy elderly. Plos One. 2012;7(3):e33276.CrossRefPubMedPubMedCentral
38.
go back to reference Shlomchik MJ, et al. Germinal center selection and the development of memory B and plasma cells. Immunol Rev. 2012;247(1):52–63.CrossRefPubMed Shlomchik MJ, et al. Germinal center selection and the development of memory B and plasma cells. Immunol Rev. 2012;247(1):52–63.CrossRefPubMed
39.
go back to reference Ligocki AJ, et al. Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation. Genes Immun. 2013;14(5):291–301.CrossRefPubMedPubMedCentral Ligocki AJ, et al. Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation. Genes Immun. 2013;14(5):291–301.CrossRefPubMedPubMedCentral
40.
go back to reference Metcalf TU, et al. Alphavirus-induced encephalomyelitis: antibody-secreting cells and viral clearance from the nervous system. J Virol. 2011;85(21):11490–501.CrossRefPubMedPubMedCentral Metcalf TU, et al. Alphavirus-induced encephalomyelitis: antibody-secreting cells and viral clearance from the nervous system. J Virol. 2011;85(21):11490–501.CrossRefPubMedPubMedCentral
41.
go back to reference Tarawneh R, et al. Critical issues for successful immunotherapy in Alzheimer’s disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets. 2009;8(2):144–59.CrossRefPubMedPubMedCentral Tarawneh R, et al. Critical issues for successful immunotherapy in Alzheimer’s disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets. 2009;8(2):144–59.CrossRefPubMedPubMedCentral
42.
go back to reference Zotova E, et al. Inflammatory components in human Alzheimer’s disease and after active amyloid-beta42 immunization. Brain. 2013;136(Pt 9):2677–96.CrossRefPubMed Zotova E, et al. Inflammatory components in human Alzheimer’s disease and after active amyloid-beta42 immunization. Brain. 2013;136(Pt 9):2677–96.CrossRefPubMed
44.
go back to reference Bancos S, et al. Memory B cells from older people express normal levels of cyclooxygenase-2 and produce higher levels of IL-6 and IL-10 upon in vitro activation. Cell Immunol. 2010;266(1):90–7.CrossRefPubMedPubMedCentral Bancos S, et al. Memory B cells from older people express normal levels of cyclooxygenase-2 and produce higher levels of IL-6 and IL-10 upon in vitro activation. Cell Immunol. 2010;266(1):90–7.CrossRefPubMedPubMedCentral
45.
go back to reference Drzezga A, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72(17):1487–94.CrossRefPubMed Drzezga A, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72(17):1487–94.CrossRefPubMed
47.
go back to reference Gale SC, et al. APOepsilon4 is associated with enhanced in vivo innate immune responses in human subjects. J Allergy Clin Immunol. 2014;134(1):127–34. Gale SC, et al. APOepsilon4 is associated with enhanced in vivo innate immune responses in human subjects. J Allergy Clin Immunol. 2014;134(1):127–34.
48.
go back to reference Grocott HP, et al. Apolipoprotein E genotype differentially influences the proinflammatory and anti-inflammatory response to cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2001;122(3):622–3.CrossRefPubMed Grocott HP, et al. Apolipoprotein E genotype differentially influences the proinflammatory and anti-inflammatory response to cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2001;122(3):622–3.CrossRefPubMed
49.
go back to reference Le Page A, et al. NK cells are activated in amnestic mild cognitive impairment but not in mild Alzheimer’s disease patients. J Alzheimers Dis. 2015;46(1):93–107.CrossRefPubMed Le Page A, et al. NK cells are activated in amnestic mild cognitive impairment but not in mild Alzheimer’s disease patients. J Alzheimers Dis. 2015;46(1):93–107.CrossRefPubMed
50.
go back to reference Fiala M, et al. Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer’s disease. J Alzheimers Dis. 2007;11(4):457–63.CrossRefPubMed Fiala M, et al. Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer’s disease. J Alzheimers Dis. 2007;11(4):457–63.CrossRefPubMed
51.
go back to reference Ligocki AJ, et al. A distinct class of antibodies may be an indicator of gray matter autoimmunity in early and established relapsing remitting multiple sclerosis patients. ASN Neuro. 2015;7(5):1–16.CrossRef Ligocki AJ, et al. A distinct class of antibodies may be an indicator of gray matter autoimmunity in early and established relapsing remitting multiple sclerosis patients. ASN Neuro. 2015;7(5):1–16.CrossRef
52.
go back to reference Schwartz M, et al. Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight-off chronic neuroinflammation. J Autoimmun. 2014;54:8–14.CrossRefPubMed Schwartz M, et al. Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight-off chronic neuroinflammation. J Autoimmun. 2014;54:8–14.CrossRefPubMed
54.
Metadata
Title
Adaptive lymphocyte profiles correlate to brain Aβ burden in patients with mild cognitive impairment
Authors
Ann M. Stowe
Sara J. Ireland
Sterling B. Ortega
Ding Chen
Ryan M. Huebinger
Takashi Tarumi
Thomas S. Harris
C. Munro Cullum
Roger Rosenberg
Nancy L. Monson
Rong Zhang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2017
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-017-0910-x

Other articles of this Issue 1/2017

Journal of Neuroinflammation 1/2017 Go to the issue